Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma


Sendur M. A. N. , AKSOY S. , Ozdemir N. Y. , Zengin N.

INDIAN JOURNAL OF PHARMACOLOGY, cilt.46, ss.125-126, 2014 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 46 Konu: 1
  • Basım Tarihi: 2014
  • Doi Numarası: 10.4103/0253-7613.125195
  • Dergi Adı: INDIAN JOURNAL OF PHARMACOLOGY
  • Sayfa Sayıları: ss.125-126

Özet

Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.